Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

GeoVax Labs, Inc.

  • SMYRNA, Georgia
  • Public · NASDAQ: GOVX
  • 19 employees
$8.6MMarket cap
-$21.5MNet income
19Employees
GOVXNASDAQ
1995IPO

About GeoVax Labs, Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$21.5M
Total assets
$6.3M
Market cap
$8.6M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: GOVX

15-minute delayed · data by Polygon.io

Market cap
$8.6M
Open
Day range
Prev close
Volume
IPO date
Feb 1, 1995

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review GeoVax Labs, Inc..

Write a review
Explore

Similar companies

Browse all →